CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

CAR T-Cell Therapy for Follicular Lymphoma

July 2nd 2020

ZUMA-2 Trial Overview: Mantle Cell Lymphoma Impact

July 2nd 2020

LDH and ECOG Performance Tests

July 2nd 2020

Liso-cel Therapy in R/R Large B-Cell Lymphoma

July 2nd 2020

The Importance of Antigen Loss in R/R Disease

July 2nd 2020

R/R Large B-Cell Therapy in Managing Various Lymphomas

July 2nd 2020

CAR T-Cell Therapy in Managing Various Lymphomas

July 2nd 2020

Rationale for Further Development of CAR T-Cell therapy

July 2nd 2020

Expert Shares Efforts to Expand Use of CAR T-Cell Therapy to Solid Tumors

June 30th 2020

Natalie Sophia Grover, MD, discusses ongoing research with CAR T-cell therapy in hematologic malignancies, efforts examining the potential for this approach in solid tumors, and future directions and challenges with this modality.

Rapid Readouts: Initial Results of the Phase III BOSTON Study

June 29th 2020

Axi-Cel Elicits Encouraging Activity in Indolent Follicular Lymphoma, Marginal Zone Lymphoma

June 24th 2020

Caron Jacobson, MD, discusses the initial ZUMA-5 findings and the next steps with axicabtagene ciloleucel in follicular lymphoma and marginal zone lymphoma.

Axi-Cel Retreatment Demonstrates Clinical Efficacy in Large B-Cell Lymphoma

June 24th 2020

Findings from an exploratory analysis of the phase 1/2 ZUMA-1 trial demonstrated clinical efficacy in patients with relapsed/refractory large B-cell lymphoma who were retreated with the CAR T-cell therapy axicabtagene ciloleucel.

Berdeja Projects Promising Future for JNJ-4528 in Relapsed/Refractory Myeloma

June 24th 2020

Jesus G. Berdeja, MD, further discusses other exciting trials in multiple myeloma and CAR T therapy being presented at the 2020 ASCO Virtual Scientific Program.

Axi-Cel Induces Durable Remissions in Relapsed CLL, B-Cell Lymphoma

June 18th 2020

Patients with relapsed chronic lymphocytic leukemia and B-cell lymphoma who received the anti-CD19 CAR T-cell therapy FMC63-28Z experienced highly durable rates of remission, according to long-term data from a phase 1/2 study.

Dr. Sauter on Off-The-Shelf Versus Autologous CAR T-Cell Products in Hematologic Malignancies

June 12th 2020

Craig Sauter, MD, discusses the differences between off-the-shelf and autologous chimeric antigen receptor T-cell products in patients with hematologic malignancies.

Dr. Jacobson on the Safety Profile of Axi-Cel in Relapsed/Refractory Indolent Lymphoma

June 5th 2020

Caron Jacobson, MD, discusses the safety profile of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.

Off-the-Shelf CAR-T Cell Therapy ALLO-501 Induces High Responses in Relapsed/Refractory B-Cell Lymphomas

May 30th 2020

The allogeneic CAR-T cell therapy ALLO-501, paired with the monoclonal antibody ALLO-647, demonstrated clinical responses and manageable toxicity in patients with pretreated large B-cell and follicular lymphomas.

Updated CARTITUDE-1 Results Continue to Demonstrate Safety, Durable Responses for JNJ-4528 in R/R Multiple Myeloma

May 29th 2020

The chimeric antigen receptor T-cell therapy, JNJ-4528, continued to demonstrate deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma, according to updated findings from the phase 1b/2 CARTITUDE-1 (NCT03548207) trial.

Tisagenlecleucel Enhances Health-Related QoL in Relapsed/Refractory DLBCL

May 22nd 2020

Tisagenlecleucel led to clinically meaningful and durable improvements in health-related quality of life in patients with relapsed/refractory diffuse large B-cell lymphoma who achieved a complete or partial response to the CD19-directed CAR T-cell therapy in the phase 2 JULIET trial.

FDA Extends Review Period for Liso-Cel in Large B-Cell Lymphoma

May 6th 2020

The FDA has extended the review period for a biologics license application for lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma.